ArticleCell stem cell2013
To be immunogenic, or not to be: that's the iPSC question.
Article in Cell stem cell, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 77 citations in OpenAlex.
- Stem cell-based therapy for fibrotic diseases: mechanisms and pathways.Stem cell research & therapy · 2024Review
- Engineered T cells from induced pluripotent stem cells: from research towards clinical implementation.Frontiers in immunology · 2023Review
- Novel Approaches to Program Cells to Differentiate into Cardiomyocytes in Myocardial Regeneration.Reviews in cardiovascular medicine · 2022Review
- Macrophages derived from pluripotent stem cells: prospective applications and research gaps.Cell & bioscience · 2022Review
- Review
- Generation of hypoimmunogenic T cells from genetically engineered allogeneic human induced pluripotent stem cells.Nature biomedical engineering · 2021Article
- Review
- Engineering Human Cardiac Muscle Patch Constructs for Prevention of Post-infarction LV Remodeling.Frontiers in cardiovascular medicine · 2021Review
- Stem cell therapies for retinal diseases: from bench to bedside.Journal of molecular medicine (Berlin, Germany) · 2020Review
- Orally bioavailable glutamine antagonist prodrug JHU-083 penetrates mouse brain and suppresses the growth of MYC-driven medulloblastoma.Translational oncology · 2019Article
- Enhanced wound healing promotion by immune response-free monkey autologous iPSCs and exosomes vs. their allogeneic counterparts.EBioMedicine · 2019Article
- Transplantation of Human Chorion-Derived Cholinergic Progenitor Cells: a Novel Treatment for Neurological Disorders.Molecular neurobiology · 2019Article
- Pluripotent stem cell-based therapy for Parkinson's disease: Current status and future prospects.Progress in neurobiology · 2018Review
- The Hippocampal Neuro-Glio-Vascular Network: Metabolic Vulnerability and Potential Neurogenic Regeneration in Disease.Brain plasticity (Amsterdam, Netherlands) · 2018Review
- Transflammation: Innate immune signaling in nuclear reprogramming.Advanced drug delivery reviews · 2017Review
- Review
- Efficient Killing of Murine Pluripotent Stem Cells by Natural Killer (NK) Cells Requires Activation by Cytokines and Partly Depends on the Activating NK Receptor NKG2D.Frontiers in immunology · 2017Article
- New strategies for improving stem cell therapy in ischemic heart disease.Heart failure reviews · 2016Review
- Blood Derived Induced Pluripotent Stem Cells (iPSCs): Benefits, Challenges and the Road Ahead.Journal of Alzheimer's disease & Parkinsonism · 2016Article
- Tumourigenicity and Immunogenicity of Induced Neural Stem Cell Grafts Versus Induced Pluripotent Stem Cell Grafts in Syngeneic Mouse Brain.Scientific reports · 2016Article
Corrections and comments
- Comment on
- Comment on
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The unexpected finding that autologous induced pluripotent stem cell (iPSC)-derived teratomas are immunogenic in syngeneic hosts sparked pessimism over their therapeutic potential; however, two recent reports (Guha et al., 2013 and Araki et al., 2013; the latter in this issue of Cell stem cell) contradict previous findings, showing no immunogenicity of in vitro differentiated syngeneic iPS-derived cells and supporting their safety.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.